Literature DB >> 23647893

Fractional flow reserve: intracoronary versus intravenous adenosine induced maximal coronary hyperemia.

P S Sandhu1, Upendra Kaul, R K Gupta, Tapan Ghose.   

Abstract

BACKGROUND: Fractional Flow Reserve (FFR), a measure of coronary stenosis severity is based on the achievement of maximal hyperemia of coronary microcirculation. The most widely used pharmacological agent is adenosine which is administered either by intra coronary or intra venous routes. IV route is time consuming, has more side effects and expensive. This study is undertaken to compare the two routes of administration.
METHODS: FFR was assessed in 50 patients with 56 intermediate focal lesions using both IV and intracoronary (IC) adenosine. FFR was calculated as the ratio of the distal coronary pressure to the aortic pressure at maximal hyperemia.
RESULTS: A total of 25 left anterior descending, 8 right, 21 circumflex, and 2 left main coronary arteries were evaluated. The mean percent stenosis was 63.91 ± 13.13 SD and, the mean FFR was 0.831 ± 0.0738 SD for IV and 0.832 ± 0.0707 SD for IC adenosine. There was a strong and linear correlation between 2 sets of observations with IV dose and IC adenosine dose (R = 0.964, y = 0.065 + 0.923x; p < 0.001) (y = IV dose, x = IC dose). The agreement between the two sets of measurements was also high, with a mean difference of: 0.001 ± 0.0197. The changes in heart rate and blood pressure were significantly higher in IV adenosine group. Different incremental doses were well tolerated, with fewer systemic adverse events with IC adenosine. Transient AV blocks were observed with both IV and IC adenosine.
CONCLUSIONS: This study suggests that IC adenosine is equivalent to IV infusion for the determination of FFR. The administration of IC adenosine is easy to use, cost effective, safe and associated with fewer systemic events.
Copyright © 2013 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23647893      PMCID: PMC3860809          DOI: 10.1016/j.ihj.2013.02.006

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  15 in total

1.  Coronary pressure measurement after stenting predicts adverse events at follow-up: a multicenter registry.

Authors:  Nico H J Pijls; Volker Klauss; Uwe Siebert; Eric Powers; Kenji Takazawa; William F Fearon; Javier Escaned; Yukio Tsurumi; Takashi Akasaka; Habib Samady; Bernard De Bruyne
Journal:  Circulation       Date:  2002-06-25       Impact factor: 29.690

2.  Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve?

Authors:  Gianni Casella; Marcus Leibig; Thomas M Schiele; Reiner Schrepf; Victoria Seelig; Hans-Ulrich Stempfle; Petra Erdin; Johannes Rieber; Andreas König; Uwe Siebert; Volker Klauss
Journal:  Am Heart J       Date:  2004-10       Impact factor: 4.749

3.  Effects of intravenous and intracoronary adenosine 5'-triphosphate as compared with adenosine on coronary flow and pressure dynamics.

Authors:  A Jeremias; S D Filardo; R J Whitbourn; R S Kernoff; A C Yeung; P J Fitzgerald; P G Yock
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

4.  Effects of adenosine on human coronary arterial circulation.

Authors:  R F Wilson; K Wyche; B V Christensen; S Zimmer; D D Laxson
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

5.  Adequacy of intracoronary versus intravenous adenosine-induced maximal coronary hyperemia for fractional flow reserve measurements.

Authors:  A Jeremias; R J Whitbourn; S D Filardo; P J Fitzgerald; D J Cohen; E M Tuzcu; W D Anderson; A A Abizaid; G S Mintz; A C Yeung; M J Kern; P G Yock
Journal:  Am Heart J       Date:  2000-10       Impact factor: 4.749

Review 6.  Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease.

Authors:  E J Topol; S E Nissen
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

7.  Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty.

Authors:  N H Pijls; J A van Son; R L Kirkeeide; B De Bruyne; K L Gould
Journal:  Circulation       Date:  1993-04       Impact factor: 29.690

8.  Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.

Authors:  Bernard De Bruyne; Nico H J Pijls; Bindu Kalesan; Emanuele Barbato; Pim A L Tonino; Zsolt Piroth; Nikola Jagic; Sven Möbius-Winkler; Sven Mobius-Winckler; Gilles Rioufol; Nils Witt; Petr Kala; Philip MacCarthy; Thomas Engström; Keith G Oldroyd; Kreton Mavromatis; Ganesh Manoharan; Peter Verlee; Ole Frobert; Nick Curzen; Jane B Johnson; Peter Jüni; William F Fearon
Journal:  N Engl J Med       Date:  2012-08-27       Impact factor: 91.245

9.  Intravenous adenosine: continuous infusion and low dose bolus administration for determination of coronary vasodilator reserve in patients with and without coronary artery disease.

Authors:  M J Kern; U Deligonul; S Tatineni; H Serota; F Aguirre; T C Hilton
Journal:  J Am Coll Cardiol       Date:  1991-09       Impact factor: 24.094

10.  Fractional flow reserve. A useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow.

Authors:  N H Pijls; B Van Gelder; P Van der Voort; K Peels; F A Bracke; H J Bonnier; M I el Gamal
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

View more
  2 in total

1.  Differences between automatically detected and steady-state fractional flow reserve.

Authors:  Tobias Härle; Sven Meyer; Felix Vahldiek; Albrecht Elsässer
Journal:  Clin Res Cardiol       Date:  2015-07-25       Impact factor: 5.460

2.  Assessment of increasing intravenous adenosine dose in fractional flow reserve.

Authors:  David Sparv; Matthias Götberg; Jan Harnek; Tobias Persson; Bjarne Madsen Hardig; David Erlinge
Journal:  BMC Cardiovasc Disord       Date:  2017-02-14       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.